About Praxis Precision Medicines, Inc.
https://www.praxismedicines.comPraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance.
CEO
Marcio Silva De'Souza
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-11-29 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 3 of 147
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:2.76M
Value:$824.9M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:2.37M
Value:$708.57M
BLACKROCK, INC.
Shares:1.8M
Value:$537.55M
Summary
Showing Top 3 of 159
About Praxis Precision Medicines, Inc.
https://www.praxismedicines.comPraxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $12.56M ▼ | $-73.93M ▼ | 0% | $-3.36 ▼ | $-73.92M ▲ |
| Q2-2025 | $0 | $13.06M ▼ | $-71.13M ▼ | 0% | $-3.31 ▼ | $-76.02M ▼ |
| Q1-2025 | $0 ▼ | $13.92M ▼ | $-69.3M ▼ | 0% ▲ | $-3.29 ▼ | $-74.68M ▼ |
| Q4-2024 | $7.46M ▲ | $15.13M ▼ | $-58.68M ▼ | -786.27% ▲ | $-2.94 ▼ | $-63.91M ▼ |
| Q3-2024 | $302K | $15.26M | $-51.91M | -17.19K% | $-2.75 | $-56.74M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $267.16M ▼ | $396.39M ▼ | $52.88M ▲ | $343.5M ▼ |
| Q2-2025 | $301.27M ▼ | $452.83M ▼ | $48.61M ▲ | $404.22M ▼ |
| Q1-2025 | $327.99M ▼ | $478.74M ▼ | $39.52M ▲ | $439.21M ▼ |
| Q4-2024 | $392.57M ▲ | $483.11M ▲ | $37.66M ▲ | $445.45M ▲ |
| Q3-2024 | $357.03M | $416.26M | $33.59M | $382.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-73.93M ▼ | $-64.74M ▼ | $50.41M ▲ | $6.44M ▼ | $-7.89M ▲ | $-64.74M ▼ |
| Q2-2025 | $-71.13M ▼ | $-54.68M ▼ | $17.89M ▲ | $28.63M ▼ | $-8.15M ▲ | $-54.8M ▼ |
| Q1-2025 | $-69.3M ▼ | $-52.71M ▲ | $-51.06M ▼ | $53.97M ▼ | $-49.8M ▼ | $-52.71M ▲ |
| Q4-2024 | $-58.68M ▼ | $-56.12M ▼ | $-10.92M ▼ | $113.77M ▲ | $46.73M ▲ | $-56.12M ▼ |
| Q3-2024 | $-51.91M | $-27.5M | $49.57M | $1.44M | $23.5M | $-27.5M |
Revenue by Products
| Product | Q4-2023 | Q4-2024 | Q1-2024 | Q2-2024 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Option Exercise Fee | $0 ▲ | $10.00M ▲ | $0 ▼ | $0 ▲ |
CEO
Marcio Silva De'Souza
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-11-29 | Reverse | 1:15 |
ETFs Holding This Stock
Summary
Showing Top 3 of 147
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 12
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:2.76M
Value:$824.9M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:2.37M
Value:$708.57M
BLACKROCK, INC.
Shares:1.8M
Value:$537.55M
Summary
Showing Top 3 of 159